WXXWY and 1FW2 Related Headlines
Go Back- WuXi Biologics Reports Strong Profitable Growth in H1 2026
- WuXi Biologics Recognized for Industry Top Sustainable Biopharma Practices Empowering the Industry's Transformation Through Green CRDMO
- WuXi Biologics Recognized by FTSE4Good for the Sixth Consecutive Year, Underscoring Value Creation Through Green CRDMO
- WuXi Biologics' MFG8 Drug Substance Facility Secures FDA PLI Approval, Advancing Commercial Supply of a Potential Blockbuster Autoimmune Therapy
- WuXi Biologics Achieves MSCI ESG AAA Rating and MSCI Selection Indexes Inclusion for Fourth Consecutive Year
- WuXi Biologics Receives Brazil ANVISA GMP Certification to Enable Global Commercial Manufacturing of Innovative Cancer Immunotherapy
- WuXi Biologics' 25th Drug Substance Facility Completes First GMP Production, Manufacturing Process Execution with Zero Deviations
- WuXi Biologics' Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Market
- WuXi Biologics Ireland Wins Top Honors at the 2026 Life Sciences Industry Awards
- WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility
- WuXi Biologics Named to CDP Supplier Engagement Assessment A List for the Second Consecutive Year
- WuXi Biologics Achieves GMP Release of 18th Drug Product Facility, Advancing Integrated Drug Substance to Drug Product Capabilities
- WuXi Biologics Included in 2026 Dow Jones Best‑in‑Class World Index and Emerging Markets Index
- WuXi Biologics Releases 2025 Sustainability Report, Advancing Sustainable Growth and Improving Healthcare Access
- WuXi Biologics Chengdu Microbial Commercial Manufacturing Site Achieves Structural Completion and Key Equipment Arrival
- WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics
- WuXi Biologics Recognized by Morningstar Sustainalytics as Industry and Regional ESG Leader for Sixth Year
- WuXi Biologics Achieves ISO 13485 Certification, Signifying Strong Capabilities in Drug-Device Combination Product Development and Manufacturing
- WuXi Biologics Honored with CDMO Leadership Awards for Ninth Consecutive Year
- WuXi Biologics Reports Record 2025 Annual Results, Operational Excellence Driven by Digital-Native Architecture
- WuXi Biologics Reports Record 2025 Annual Results
- World Water Day: WuXi Biologics Advances Water Stewardship and Achieves Water Target
- WuXi Biologics Wins Multiple Asia-Pacific Biopharma Excellence Awards for Leadership in Bioprocessing, Manufacturing Excellence, and Digital Innovation
- WuXi Biologics Included in S&P Global Sustainability Yearbook for Fourth Consecutive Year
- WuXi Biologics Awarded EcoVadis Platinum Medal for Third Consecutive Year, Ranking Among Top 1% Globally
- WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager
- WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody
- JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth
- WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic
- WuXi Biologics Launches Industry-Leading Digital Twin Platform PatroLab™ Designed to Transform Bioprocessing and Manufacturing
- WuXi Biologics Achieves ISO 20400 Certification, Setting Benchmark in Sustainable Procurement
- WuXi Biologics Recognized by Hong Kong ESG Reporting Awards 2025 for Outstanding ESG Disclosure
- WuXi Biologics Achieves CDP Highest "A" Ratings in Both Climate Change and Water Security
- WuXi Biologics Extends Global CRDMO Network to Qatar Through Strategic MoU Signed with Qatar Free Zones Authority
- WuXi Biologics Included in Hang Seng Corporate Sustainability Benchmark Index
- WuXi Biologics Honored with 2025 Global Customer Value Leadership Recognition by Frost & Sullivan
- WuXi Biologics Receives MSCI AAA ESG Rating for Third Consecutive Year
WXXWY and 1FW2 Related Press Releases
Go Back- WuXi Biologics Reports Strong Profitable Growth in H1 2026
- WuXi Biologics Recognized for Industry Top Sustainable Biopharma Practices Empowering the Industry's Transformation Through Green CRDMO
- WuXi Biologics Recognized by FTSE4Good for the Sixth Consecutive Year, Underscoring Value Creation Through Green CRDMO
- WuXi Biologics' MFG8 Drug Substance Facility Secures FDA PLI Approval, Advancing Commercial Supply of a Potential Blockbuster Autoimmune Therapy
- WuXi Biologics Achieves MSCI ESG AAA Rating and MSCI Selection Indexes Inclusion for Fourth Consecutive Year
- WuXi Biologics Receives Brazil ANVISA GMP Certification to Enable Global Commercial Manufacturing of Innovative Cancer Immunotherapy
- WuXi Biologics' 25th Drug Substance Facility Completes First GMP Production, Manufacturing Process Execution with Zero Deviations
- WuXi Biologics' Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Market
- WuXi Biologics Ireland Wins Top Honors at the 2026 Life Sciences Industry Awards
- WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility
- WuXi Biologics Named to CDP Supplier Engagement Assessment A List for the Second Consecutive Year
- WuXi Biologics Achieves GMP Release of 18th Drug Product Facility, Advancing Integrated Drug Substance to Drug Product Capabilities
- WuXi Biologics Included in 2026 Dow Jones Best‑in‑Class World Index and Emerging Markets Index
- WuXi Biologics Releases 2025 Sustainability Report, Advancing Sustainable Growth and Improving Healthcare Access
- WuXi Biologics Chengdu Microbial Commercial Manufacturing Site Achieves Structural Completion and Key Equipment Arrival
- WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics
- WuXi Biologics Recognized by Morningstar Sustainalytics as Industry and Regional ESG Leader for Sixth Year
- WuXi Biologics Achieves ISO 13485 Certification, Signifying Strong Capabilities in Drug-Device Combination Product Development and Manufacturing
- WuXi Biologics Honored with CDMO Leadership Awards for Ninth Consecutive Year
- WuXi Biologics Reports Record 2025 Annual Results, Operational Excellence Driven by Digital-Native Architecture
- WuXi Biologics Reports Record 2025 Annual Results
- World Water Day: WuXi Biologics Advances Water Stewardship and Achieves Water Target
- WuXi Biologics Wins Multiple Asia-Pacific Biopharma Excellence Awards for Leadership in Bioprocessing, Manufacturing Excellence, and Digital Innovation
- WuXi Biologics Included in S&P Global Sustainability Yearbook for Fourth Consecutive Year
- WuXi Biologics Awarded EcoVadis Platinum Medal for Third Consecutive Year, Ranking Among Top 1% Globally
- WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager
- WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody
- JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth
- WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic
- WuXi Biologics Launches Industry-Leading Digital Twin Platform PatroLab™ Designed to Transform Bioprocessing and Manufacturing
- WuXi Biologics Achieves ISO 20400 Certification, Setting Benchmark in Sustainable Procurement
- WuXi Biologics Recognized by Hong Kong ESG Reporting Awards 2025 for Outstanding ESG Disclosure
- WuXi Biologics Achieves CDP Highest "A" Ratings in Both Climate Change and Water Security
- WuXi Biologics Extends Global CRDMO Network to Qatar Through Strategic MoU Signed with Qatar Free Zones Authority
- WuXi Biologics Included in Hang Seng Corporate Sustainability Benchmark Index
- WuXi Biologics Honored with 2025 Global Customer Value Leadership Recognition by Frost & Sullivan
- WuXi Biologics Receives MSCI AAA ESG Rating for Third Consecutive Year
